This study is for patients that have been diagnosed with PD-L1 Positive Head and Neck Squamous Cell Carcinoma (HNSCC). Specifically, for people with this type of cancer that cannot be treated with surgery or radiation treatment and has not been treated for cancer that spread to sites distant from the head and neck region (metastatic) or for cancer that returned or got worse after being treated (recurrent).The investigational drug (not approved by the FDA) in this study is GSK3359609. The purpose of this research study is to find out if GSK3359609 combined with pembrolizumab works better than the single drug pembrolizumab. Participants can expect to receive treatment for about 3 years and be in follow-up for the rest of their life.
This study is for patients that have been diagnosed with differentiated thyroid cancer (DTC). The investigational drug used in this study is cabozantinib. The purpose of this study is to evaluate the effect of cabozantinib compared with a placebo in treating patients whose disease has progressed after receiving prior treatment with drugs that inhibit growth of tumor blood vessel (VEGFR-targeted therapy) for their thyroid cancer. Participants can expect to be on this study for about a year including 9 months of treatment, a follow-up visit 4 weeks after treatment and 3 months of follow up.
This study is for patients with low-risk, Human Papillomavirus (HPV) positive oropharyngeal cancer. The first part of the study is to determine if a reduced dose of radiation along with chchemotherapy or immunotherapy result in the same length of time without the cancer getting worse as the usual approach. The second part of this study is being done to also see if quality of life with a reduced dose of radiation with chemotherapy or immunotherapy than the usual approach.
Head and neck cancer arises in cosmetically and functionally critical areas of the face. As a result of head and neck cancer and its treatment, head and neck cancer survivors face significant issues related to disfigurement, difficulty swallowing, and challenges speaking. Unfortunately, we do not have effective ways to treat body image concerns in head and neck cancer survivors. Therefore we developed BRIGHT (Building a Renewed ImaGe after Head & neck cancer Treatment), a new telemedicine intervention for head and neck cancer survivors with body image concerns. The purpose of this study is to evaluate the effectiveness of BRIGHT as a new treatment strategy for head and neck cancer survivors with body image concerns.
This study is for patients that have been diagnosed with head and neck squamous cell cancer (HNSCC). The investigational drug in this study is ADU-S100. The purpose of this study is to find out how ADU-S100 and pembrolizumab (also called KEYTRUDA®) interact with the immune system to potentially treat cancer and to make sure the drugs are safe to use together. Participants can expect to recieve treatment for up to two years. This would include 2 doses in a3-week cycle for up to 35 cycles. Participants can expect follow-up to continue every eight weeks until completion of the required safety reporting periods, death, withdrawal of consent, loss to follow-up, or close of study by the Sponsor.
This study is for patients with HPV positive oropharynx cancer. The purpose is to determine if maintenance nivolumab following definitive therapy with radiation and chemotherapy (cisplatin) result in significat improvement in overall survival (OS) (time being alive) and progression-free survival (PFS) (time being alive without cancer).
The purpose of this study is to evaluate whether a new patient navigation intervention can decrease delays starting radiation therapy after surgery for white and African-American head and neck cancer patients. Patients who have surgery and radiation for certain types of head and neck cancer are eligible for this study.
The purpose of this study is to determine at what dose the study drug (ASP1948) is safe and tolerated and how it is processed in the blood of patients with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. When the safe dose is identified, it will be used to evaluate if the study treatment causes tumors to shrink in patients.The screening period for this study can take up to 28 days. The treatment period consists of up to 48 weeks of initial treatment, followed by up to 45 weeks of follow up. If you quality and are willing to continue in the re-treatment period (receiving the study drug again), you will be in the study for an additional 48 weeks.
This study is for patients who have been diagnosed with locally advanced squamous cell carcinoma of the head and neck (SCCHN) and will need additional treatment following surgery. The investigational drug in this study is Durvalumab. The purpose of this study is to investigate other drugs that may be combined with radiation to treat SCCHN. The study focuses on determining whether durvalumab combined with radiation will have improved 3-year disease free survival compared to historical control. Participants can expect to be in this study for 5 years.
This study is for patients that have been diagnosed with with resectable High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC). The investigational drug used in this study is Pembrolizumab. The purposes of this study are to: determine how well pembrolizumab keeps the cancer from coming back or spreading as compared to placebo, determine if giving pembrolizumab after surgery and radiation helps patients live longer, and to test the safety of the study drug and see how patients' bodies handle it. Participants can expect to be in this study for about 8 years. This includes the time that participants will be on study drug and in follow up to see if the cancer has come back or spread.